August 25, Mindray (300760.SZ) announced financial results for the first half ended June 30, 2021. The first-half sales of CNY 12.778 billion increased 20.96% year-on-year. The net earnings attributable to common stockholders was CNY 4.344 billion, increasing 25.79% than the one in the last year.

AccessDx Holdings said Wednesday that it has acquired 2bPrecise, a service and technology provider that integrates genetic and genomic test results into electronic health records, from EHR giant Allscripts Healthcare Solutions for an undisclosed amount.

Becton Dickinson announced Wednesday that it has received US Food and Drug Administration approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus.

On August 20, Fosun Diagnostics, a holding subsidiary of Fosun Pharma, signed the investment agreement with Suzhou Abcarta. After the completion of the transaction, Fosun Diagnostics will hold about 58.67% equity of Suzhou Abcarta.

Genetron Health on Tuesday reported a 38 percent year-over-year increase in its second quarter revenues amid strong growth in sales from its LDT and IVD segments.

Cerba Research and ACT Genomics said on Tuesday that they have formed a joint venture to provide clinical trial services to clients throughout Asia Pacific through a new laboratory facility in Taiwan.

Recently, SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) developed by Joinstar Biomedical Technology Co., Ltd. and Nanshan Pharmaceutical Research Institute of Guangdong province was officially sold to overseas markets.

On August 21, TELLGEN posted a 157.93% year-over-year increase on continued demand for its tumor and autoimmunity test.

Point-of-care diagnostics firm LumiraDx and special purpose acquisition company CA Healthcare Acquisition said on Monday that they have revised the terms of their previously announced merger to lower the equity value of the combined company.

AnPac Bio-Medical Science, a cancer screening and detection company, said on Monday that it has filed for registration testing of its Class III, multi-cancer detection device with China's National Medical Products Administration.

The European Commission has opened an investigation assess whether Illumina's decision to complete its acquisition of Grail is a breach of the “standstill obligation”

Waltham, MA-based Thermo Fisher Scientific was granted emergency use authorization for the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and the TaqPath COVID-19 RNase P Combo Kit 2.0 assays.

Amoy Diagnostics and Amgen on Thursday said that they have entered a strategic partnership to develop a companion diagnostic for the Japanese market to identify non-small cell lung cancer patients for Amgen's KRAS G12C inhibitor, sotorasib (Lumakras).

Partek said that it has entered into an agreement with Santa Clara, California-based Agilent Technologies to integrate its Partek Flow bioinformatics software with the Agilent Alissa Clinical Informatics platform, providing an end-to-end analysis workflow that is customizable for Agilent's customers

As the first share of POCT in China, Wondfo will continue to be driven by innovation and cooperation in 2021, implement both epidemic business, conventional business, and double-cycle in domestic and abroad.

South Korean diagnostics company Seegene on Wednesday reported a nearly 11 percent year-over-year increase in its second quarter revenues amid higher sales of its infectious disease testing reagents and PCR equipment in Europe and North America.

Twist Bioscience and SomaLogic announced on Wednesday a partnership to discover novel therapeutic targets and antibodies.

Illumina, Inc. today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a pre-commercial company founded to accelerate early screening of cancer.

The Precede consortium and Konica Minolta Precision Medicine said Tuesday that KMPM and its subsidiaries, Ambry Genetics and Invicro, have partnered with the international effort to advance diagnostic and screening approaches for pancreatic cancer early detection.

Tempus said on Tuesday that it has submitted a premarket approval application for its next-generation sequencing-based xT-Onco tumor profiling assay to the US Food and Drug Administration.